TwoStep Therapeutics

NEWLY RELEASED AGENDA!💡 The field of conjugatable drugs is advancing at a rapid pace towards more targeted, safer and efficacious novel bioconjugates, with major collaborations like Nurix & Seagen for antibody-degrader conjugates and Sotio Biotech & Biocytogen for bispecific ADCs. The 4th Novel Conjugates Summit returns to shine a spotlight on the latest innovations in targeting vectors and payloads for bioconjugates, including antibody-degrader conjugates, bispecific ADCs & peptide drug conjugates. Hear from the following industry leaders: Akihiko Yamamoto, Eisai Andrew Buesking, Prelude Therapeutics Arnaud Tiberghien, Bicycle Therapeutics Arne Scheu, Valink Therapeutics Caitlyn Miller, TwoStep Therapeutics Christian Marsolais, Theratechnologies Inc. Chris Leamon, Fusion Pharmaceuticals David White, ProteinQure Dong Xu, OBI Pharma Gwenn Hansen, Nurix Hadi Falahatpisheh, ALX Oncology Hong I. Wan, Tallac Therapeutics Jarrod Longcor, Cellectar Biosciences, Inc. Jijun Dong, Salubris Biotherapeutics Kevin Hamblett, Pfizer Leo Qian, Entrada Therapeutics Marc-André Kasper, Tubulis GmbH Oliver Schon, BiVictriX Therapeutics plc Qinsi Zheng, Orum Therapeutics Stanley T. Lewis, A28 Therapeutics Thomas Natoli, Dyne Therapeutics Vicky Appleman, Takeda Vijaya R. Pattabiraman, Bright Peak Therapeutics Vimal Patel, RadioPharm Theranostics Join us to explore the most promising new targeting vectors and payloads that are set to revolutionize the landscape of conjugated drugs in 2025! Check out our BRAND NEW full event guide here: https://ter.li/xvkpoq

My answer to the platform vs asset debate in techbio: Great platforms build great assets. But, you have to be strategic. It's about balance. You can advance a lead asset, while leveraging your platform (services, targets, other assets) to gain revenue grow your platform. If you do it right, you create a cycle of growth. Our advice on striking this balance: https://lnkd.in/gVRxU7SU Quick examples below: Most companies fall somewhere on a continuum between monetizing the platform itself vs using assets to fuel platform development. Example: Twist Bioscience. They monetized a DNA synthesis platform and became a huge company. They pivoted toward assets later. But most bioplatforms aren't like that. Most need to pursue assets earlier to fuel development and show traction. Example: Mammoth Biosciences owns key IP in small CRISPR systems and has monetized various aspects of that IP through pharma deals. These partnerships boosted their credibility and funded future R&D. Now, they have strong pharma ties and millions in non-dilutive funding for internal development. My most recent essay tackles striking this balance, and what you need to show by Series A to be on the right track.

Want to learn how biotech startups get off the ground? Curious about what VCs look for in early-stage biotech companies? Interested in hearing from both a top VC partner and an incredible biotech CEO? Join us for a Fireside Chat with Caitlyn Miller, PhD (CEO of TwoStep Therapeutics) and Omri Amirav-Drory (General Partner at NFX) on October 30th! Register here: https://lu.ma/l4x8v5ik **Co-Hosted by: NFX Bio and Stanford Biotech Group**

🚀 Exciting News from TwoStep Therapeutics! 🚀 We’re delighted to welcome Caleb Perez to our team! During his doctoral studies in Biological Engineering at MIT, Caleb worked under Dr. Michael Birnbaum to engineer high-throughput platforms to optimize T cell-based immunotherapies. Outside of work, Caleb is an avid climber and basketball enthusiast. We’re thrilled to have you with us, Caleb, and we’re looking forward to all the incredible contributions you’ll make. Welcome aboard!

Currently, the integrin-targeted ADC in the clinic is Pfizer's ITB6 ADC. The differentiation of the TwoStep Therapeutics approach appears to lie in overcoming tumor antigen heterogeneity (such as integrin) through a peptide fused to the Fc or antibody rather than bi- or multi-specific antibodies. 1. Will the fusion of the two molecules be achieved via genetic fusion (directly inserting the peptide into the antibody's genetic sequence) or through chemical conjugation without altering the antibody structure? According to Caitlyn Miller, PhD's interview in Genetic Engineering & Biotechnology News, it seems they will opt for the genetic fusion approach. 2. They initially plan to use validated cytotoxic payloads. I'm interested in whether the payload release pathway will be similar to conventional ADCs or if there will be differences. Considering the recent partial clinical hold on YL202/BNT326 in phase 1 trials, could there be safety issues if the payload is released in the TME without relying on drug internalization?

If you've lost a loved one to cancer, and seen TwoStep Therapeutics science in action, you'd see why backing this team is a no-brainer. One platform aiming to target virtually any solid tumor...that really moves the needle for so many people. Excited to share the bigger vision behind why we led this seed round: https://lnkd.in/g8wgeUWe Caitlyn Miller, PhD

Thank you Uduak Grace Thomas for the interview and new article in Genetic Engineering & Biotechnology News! Uduak's article dives deeper into the science and backstory of TwoStep Therapeutics’ multi-targeted platform for oncology. Read more at Genetic Engineering & Biotechnology News 👇 https://lnkd.in/gNsMw2h3 Other links: Press Release: https://lnkd.in/gErBpaBg Endpoints article: https://lnkd.in/gx_4paV3 Company website: www.twosteptx.com

Our co-founder and CEO Caitlyn Miller, PhD spoke with Kyle LaHucik at Endpoints News about our work developing a novel tumor-targeting platform for solid tumors - and how the broad applicability of this approach opens up new possibilities for cancer treatment. Read more in Endpoints News👇  https://lnkd.in/gx_4paV3

Thrilled to be part of the TwoStep Therapeutics team! Congrats to CEO Caitlyn Miller, PhD on spearheading this important vision as we work to develop targeted therapies for solid tumors. More 👇

We’re excited to announce our official launch and the closing of a $6.5M seed round to advance our pipeline of targeted therapies for solid tumors. Our delivery platform is built around a unique tumor-targeting agent that can selectively bind five targets that are highly expressed on solid tumors. This multi-targeting feature enables broad applicability across a wide range of tumor types and patient populations, overcoming the limitations of traditional single-antigen targeting approaches. Led by co-founder and CEO Caitlyn Miller, PhD, our mission is to revolutionize cancer care by developing precise, effective, and broadly applicable targeted therapies. Our work is guided by world-class academic-entrepreneurs at Stanford, including co-founders Carolyn Bertozzi, Jennifer Cochran and Ron Levy. We launched from the Stanford University Innovative Medicines Accelerator (IMA) and are backed by a syndicate of high quality investors, led by NFX with participation from 2048 Ventures, Alexandria Real Estate Equities, Inc., Cooley LLP’s affiliated fund GC&H Investments, and the family office of the founder of Arcadia Investment Partners. Read the full press release to learn more: Press Release: https://lnkd.in/gErBpaBg Endpoints article: https://lnkd.in/gx_4paV3 Company website: www.twosteptx.com